<DOC>
	<DOC>NCT00781456</DOC>
	<brief_summary>This study is being conducted to evaluate the efficacy of a 91-day extended cycle oral contraceptive compared to placebo for decreasing the frequency and severity of menstrually-related migraine headaches.</brief_summary>
	<brief_title>A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Premenopausal, nonpregnant, nonlactating History of migraine headaches without aura for at least 6 months History of migraine headaches associated with menstruation Others as directed by FDAapproved protocol History of migraine headaches with aura or focal neurological symptoms Any contraindication to the use of oral contraceptives Others as dictated by FDAapproved protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>34 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Migraine headache</keyword>
	<keyword>menstrual</keyword>
	<keyword>oral contraceptive</keyword>
	<keyword>Menstrually-Related Migraine Headache</keyword>
</DOC>